Targeting macrophage-myofibroblast transition with <i>Caulis spatholobi</i> to attenuate renal interstitial fibrosis: integrated UHPLC-Q-Exactive Orbitrap-MS, network pharmacology, and experimental validation.

ABSTRACT:

Introduction

Caulis Spatholobi (CS), a traditional Chinese medicine, is recognized for its abilities to reduce fibrinogen levels, promote proteolysis, and improve conditions such as diabetic nephropathy. However, the potential of aqueous extract of CS (AECS) as an effective treatment for renal interstitial fibrosis (RIF) is yet to be established.

Methods

The AECS was qualitative analyzed by UHPLC-Q-Exactive Orbitrap-MS. Potential targets of AECS were predicted, and RIF disease targets were collated from databases. A Venn diagram was generated using the EVenn platform, and drug-active ingredient-target network diagrams were constructed with Cytoscape 3.10.1 software. The PPI network was generated through the STRING database, and GO and KEGG enrichment analyses were exe

SUBMITTER: Song Z 

PROVIDER: S-EPMC12546245 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature